Expert Interview
Discussing the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Ticker(s): GILDInstitution: Cancer Center of Kansas
- President of CCoK, Clinical Professor of Medicine at University of Kansas, and Founder of the Wichita Cancer Foundation
- Board certified in Medical Oncology and Hematology and treats more than 75 patients with HR+/HER2 metastatic breast cancer
- Involved in oncology research at a local and national level being the Principal Investigator of the Wichita NCI Community Oncology Research Program
What has been your clinical experience Trodelvy?
Added By: sara_adminWhat are your initial thoughts on the numbers presented for the overall survival rate in the TROPiCS-02 study?
Added By: sara_adminPlease rate your level of excitement on a scale from 1-10 for Trodelvy's potential for HR+/HER2- metastatic breast cancer.
Added By: sara_adminDoes the OS data presented at ESMO change your view at all on the use of Trodelvy? Positively or negatively?
Was the difference from the chemo of physician's choice control group meaningful?
median OS: 14.4m vs. 11.2m
12m OS rate = 61% vs. 47%
They also showed stat sig delay in health status, Quality of Life deterioration with hazard ratio 0.75.
How important was this aspect of the data?
What percentage of patients with "HER2 negative" status fall into the HER2 Low category?
Given the recent data with Enhertu for HER2 low patients from the Destiny Breast04 trial, how do you prioritize using these 2 different agents with a population that overlaps? What are the factors, if any, that will steer toward one or the other?
-
What is the trend in your Trodelvy prescribing?
Will the overall survival data at ESMO change this trend?
Does the Enhertu data impact it?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
